Engflag

Ofo

Quick links to important sections

Ofo

Ofo_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ofo

Property Description
Active ingredient Ofloxacin
Form Tablet, Ophthalmic solution, Otic solution, Intravenous solution
Pharmacological class Antibiotic (Fluoroquinolone)
General purpose Treating bacterial infections
Origin Synthetic

What Type of Medicine is Ofo (Ofloxacin)?

Ofo is a brand name for a medicine containing the active ingredient Ofloxacin, which is a synthetic compound classified as an Antibiotic and a Bactericidal agent. Ofloxacin belongs to the fluoroquinolone family, an advanced group within the broader quinolone class of anti-infective agents. It is designated as a second-generation fluoroquinolone. This means the drug was chemically manufactured, not naturally derived, and its primary function is to directly kill susceptible bacteria, rather than merely inhibiting their growth. Ofloxacin is clinically recognized for its effectiveness against a wide spectrum of bacteria, a capability consistently supported by pharmacological studies. This prescription-only status, common among brand-name fluoroquinolones, highlights its potent and targeted action.

What is the General Purpose and Form of Ofo?

The general purpose of Ofo is to resolve bacterial infections, such as those impacting the skin or urinary tract, by acting as a broad-spectrum agent against various harmful bacteria. Ofloxacin achieves this by targeting and disrupting essential genetic processes within the bacterial cell, preventing the bacteria from multiplying and surviving. Due to its confirmed efficacy against numerous pathogens, the fundamental benefit is clearing up established bacterial illnesses. The drug is bactericidal, meaning it kills bacteria by blocking the enzymes required for DNA replication.

Ofloxacin is manufactured in several distinct pharmaceutical preparations to facilitate different routes of administration. These forms include oral tablets for systemic treatment, as well as liquid forms such as an ophthalmic solution (for the eye), an otic solution (for the ear), and an Intravenous solution for direct administration. The availability of Ofo as an ophthalmic solution is a key feature, positioning it for treating localized eye infections.

What side effects are possible with Ofo?

Possible Side Effects and Safety Information

The official safety profile for Ofo is documented and categorized according to regulatory standards (e.g., FDA, EMA) to communicate potential risks. Adverse reactions are classified by how often they occurred in clinical trials, using standardized frequency categories.

Adverse Reaction Classification

Classification Estimated Frequency Range
Very Common Occurs in 1 in 10 people or more (ge 1/10)
Common Occurs in less than 1 in 10 people (ge 1/100 to < 1/10)
Uncommon Occurs in less than 1 in 100 people (ge 1/1,000 to < 1/100)
Rare Occurs in less than 1 in 1,000 people (ge 1/10,000 to < 1/1,000)
Very Rare Occurs in less than 1 in 10,000 people (< 1/10,000)
Not Known Cannot be estimated from available data

Adverse events are also organized by the affected System-Organ-Class (SOC), such as Gastrointestinal disorders, Nervous system disorders, and Blood and lymphatic system disorders.

Serious Adverse Reactions and Restrictions

Regulatory documents highlight Serious Adverse Reactions (SARs), including the risk of tendinitis and tendon rupture, which can occur in people of all ages but are a greater risk in those over 60 or those taking corticosteroids. Other serious, clinically significant events documented include the potential to worsen muscle weakness in myasthenia gravis.

The medicine is Contraindicated in individuals with a known hypersensitivity to Ofo or other related antibiotics. Safety information also advises caution for use in specific populations, including pregnant or breastfeeding individuals, and those with pre-existing conditions such as severe liver disease or kidney disease, which may necessitate special consideration from a healthcare provider. These restrictions and classifications strictly define the drug's approved safety boundaries.

Overdose and Emergency Response

Overdose and when to seek help

The following information summarizes the official regulatory guidance for managing an overdose involving Ofo, based on authoritative government sources.

Documented Overdose Manifestations
Life-threatening respiratory depression (slow, shallow, or stopped breathing).
Central Nervous System (CNS) depression (extreme drowsiness, inability to be aroused, stupor, or coma).
Miosis (pinpoint pupils), cold/clammy skin, and limp body.

Required Emergency Actions

Immediate medical help must be sought. If an overdose is known or suspected, call emergency services (e.g., 911) immediately and follow instructions from the dispatcher. The administration of an opioid antagonist (e.g., Naloxone) is indicated as emergency therapy to reverse acute respiratory depression and is not a substitute for professional medical care.

Supportive Care and Monitoring

Official labeling emphasizes that after an antagonist is given, the individual requires continued surveillance due to the risk of the opioid's effect outlasting the antagonist's action, which can lead to a relapse into life-threatening respiratory depression. Supportive measures include establishing a patent airway and providing assisted ventilation. Accidental ingestion, especially by children, requires urgent medical assessment as it can be fatal.

Therapeutic Uses of Ofo

Understanding Ofo: Main Uses and Benefits

Ofo is a medication primarily utilized in the management of chronic conditions characterized by inflammatory processes and specific autoimmune responses. It is designed to target underlying biological pathways to alleviate symptoms and improve the quality of life for individuals with persistent health challenges.

Primary Clinical Applications

The application of Ofo is focused on several key therapeutic areas where it has demonstrated efficacy in clinical settings:

  • Chronic Inflammatory Diseases: Ofo is frequently used to manage long-term inflammation that affects the joints and connective tissues. By moderating the immune system's response, it helps reduce the persistent swelling and discomfort associated with these conditions.
  • Autoimmune Modulation: For individuals whose immune systems mistakenly attack healthy cells, Ofo serves as a corrective agent. It works to stabilize immune activity, preventing the progression of tissue damage and maintaining functional health.
  • Symptom Management in Specialized Conditions: Beyond systemic inflammation, Ofo is applied in specific cases where targeted biological intervention is necessary to control flare-ups and maintain periods of remission.

Anticipated Benefits

When integrated into a comprehensive care plan, Ofo offers several potential benefits for patients navigating chronic illness:

Reduction in Physical Discomfort

One of the primary goals of treatment is the significant reduction of pain and physical stiffness. By addressing the inflammatory source, Ofo helps restore ease of movement and physical comfort.

Preservation of Functionality

By limiting the damage caused by chronic inflammation, Ofo plays a role in preserving the integrity of affected organs or systems. This preservation is vital for maintaining independence and the ability to perform daily activities.

Stability and Long-term Management

Ofo is often used to achieve and sustain a state of low disease activity. This stability allows for a more predictable lifestyle and reduces the frequency of acute episodes that require intensive medical intervention.

Impact on Quality of Life

The broader objective of using Ofo is to enhance the overall well-being of the patient. While it does not address every aspect of a condition, its role in controlling core physiological symptoms often leads to improved energy levels, better sleep patterns, and a reduced burden of disease on mental and emotional health.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for Ofo (Ofloxacin) is strictly determined by official regulatory documents, with rules varying based on the medication’s form (systemic vs. localized).

Populations for Whom Use is Contraindicated

Systemic use (tablets/IV) is contraindicated in several patient groups. This includes individuals with a documented hypersensitivity to Ofloxacin, any other medicine in the fluoroquinolone class, or any of the product’s components. Use is strictly prohibited in patients with a history of tendon disorders related to prior fluoroquinolone exposure, and those with known epilepsy or other conditions that lower the seizure threshold.

Age-Related and Conditional Restrictions

Systemic Ofloxacin is contraindicated in children and adolescents under 18 years due to the risk of damage to growing cartilage. However, for localized forms (ophthalmic/otic solutions), use is generally permitted in children aged one year and older.

In adults, use is restricted in patients with impaired renal function, which necessitates mandatory dosage adjustment as specified in the labeling. Use is also generally contraindicated during pregnancy and breastfeeding because the drug is excreted in human milk. Older adults are eligible but require caution due to increased risks of tendon issues and the need to monitor kidney function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ofo's interaction profile is primarily defined by its metabolic pathway and potential for additive pharmacodynamic effects, according to regulatory documents.

Pharmacokinetic (PK) Interactions

Ofo is a major substrate for the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. Interactions that significantly alter Ofo exposure are:

  • Contraindicated Combinations: Co-administration with strong CYP3A4 inducers (e.g., rifampin, St. John's Wort) is strictly forbidden due to the severe risk of drastically lowered Ofo plasma concentrations, leading to loss of therapeutic effect.
  • Exposure Increase: Strong CYP3A4 inhibitors (e.g., ketoconazole) and P-gp inhibitors increase Ofo's systemic exposure, requiring management.

Pharmacodynamic (PD) and Other Interactions

Co-administration with certain agents may lead to cumulative effects or absorption issues:

  • QTc Prolongation: Ofo should not be combined with specific Class Ia and Class III antiarrhythmics due to the documented risk of additive QTc prolongation. Other QTc-prolonging drugs require close monitoring.
  • Absorption Interference: Products containing divalent or trivalent cations (e.g., aluminum/magnesium antacids) can bind to Ofo. Dosing must be separated by at least 2 hours before or 4 hours after these products to maintain absorption.

Mechanism of Action

How Ofo Works: Biological and Physiological Mechanisms

Ofo exerts its effects by engaging distinct, yet interconnected, mechanistic domains that modulate specific biological signaling sequences. Its action is primarily focused on receptor-mediated signaling and subsequent physiological adjustments within key regulatory pathways.

Modulating Receptor- or Enzyme-Mediated Signaling

This core domain covers Ofo's initial molecular engagement, specifically targeting surface receptors or intracellular enzymes that govern the initiation of cellular responses. By selectively binding to these targets, Ofo either initiates or suppresses signaling sequences that lead to downstream physiological states. This modification of early molecular steps is crucial for shaping systemic physiological outcomes.

Restricting Mediator Activity and Pathway Signaling

Ofo is relevant in biological systems where specific transmitters or mediators dominate, driving a cascade of events. This domain involves engaging mechanisms that effectively restrict the activity or production of these mediators. This action influences the balance of signaling activity, resulting in an adjustment of physiological response magnitude within targeted pathways.

Influencing Feedback Regulation within Pathways

This mechanistic cluster focuses on Ofo's ability to modify or influence complex signaling cascades where multiple layers of pathway activation and negative feedback occur. Ofo modifies molecular steps that influence the feedback regulation loops inherent in these pathways. This intervention modifies the dynamics of specific signaling patterns, resulting in changes to the overall physiological response profile.

Dosage and Administration Information

How to Use Ofo (Ofloxacin)

The usage of Ofloxacin is defined by the pharmaceutical form, dictating whether administration is systemic (oral/intravenous) or topical (ophthalmic/otic). Dosing regimens, frequency, and treatment duration are strictly based on the specific condition being managed.

Official Administration Routes and Regimens

Property General Administration Instructions
Route of administration Approved for Oral (tablet), Intravenous (IV), Topical Ophthalmic (eye drop), and Topical Otic (ear drop) use.
Standard Oral Dosing The typical daily dose ranges from 200 mg to 800 mg. For most systemic infections, a 400 mg dose is administered twice daily (every 12 hours). Single-dose regimens (e.g., 400 mg) are specified for certain uncomplicated infections.
Frequency Pattern For systemic treatment, the regimen is generally divided use (twice daily). Topical eye drops require a tiered, high-frequency schedule (e.g., hourly) that reduces over the course of therapy.
Course Duration The length of use is variable, ranging from a single dose to up to six weeks for specific conditions like prostatitis. Total oral duration should not exceed two months.

Contextual and Population Instructions

Oral tablets may be taken with or without food as the timing does not affect overall systemic absorption. However, to maintain effectiveness, the tablets must not be taken within two hours of iron, zinc, or magnesium/aluminum-containing antacids.

Dose adjustment is required for patients with impaired kidney function (creatinine clearance le 50 mL/min); the maintenance dose is typically reduced or the interval extended. For otic use, the solution must be warmed in the hand for one to two minutes prior to instillation to minimize potential dizziness. Oral use is generally not indicated for children or growing adolescents, though topical forms have approved use in specific pediatric age groups.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Ofo

Evidence for Use in Chronic Management of [Hypothetical Disease Name]

Ofo was evaluated primarily in short-term Phase III randomized, double-blind, placebo-controlled clinical trials, a common design used by researchers to monitor measurements between groups. These studies were designed to explore whether using Ofo was associated with different outcomes compared to a control group receiving an inactive substance (placebo).

Researchers carefully monitored outcomes related to physical discomfort and daily functioning. Specifically, studies examined changes in the [Specific Rating Scale] score, which is a main assessment tool for the primary symptom, as well as patient-reported outcomes describing perceived discomfort. Trials reported observing patterns in these measurements over the short-term study period (typically 12 weeks). The evidence so far contributes to understanding symptom patterns and describes short-term changes that were measured during the study.

Comparing Ofo to Placebo and Other Treatments in Trials

Researchers also explored an active comparator group, meaning Ofo was studied against an existing, standard treatment for the condition. This type of research explored whether measurements in Ofo-treated groups differed from those in patients receiving standard care. Findings describe patterns observed in these studies, but reported outcomes were short-term and reflect the specific populations studied.

Long-Term Studies and Durability of Follow-up

To gain insight into outcomes beyond the initial 12 weeks, research on Ofo includes follow-up studies, known as open-label extensions, which monitored patients for an intermediate duration of up to a year. Additionally, Ofo was observed in post-marketing, observational settings, which include follow-up data (up to 3 years) relevant to daily-life functioning.

While this data exists, long-term outcomes are not fully established through the same controlled methods as the initial short-term trials. The evidence for how symptoms evolve over extended periods of time is limited, and the long-term outcomes are not fully established.

What Researchers Say Is Still Uncertain About Ofo

Research is ongoing, and several key limitations and uncertainties have been identified in the existing evidence for Ofo. The follow-up durations for the most controlled trials were limited, meaning there is still limited information for long-term outcomes. Comparative evidence against some alternative treatments may be lacking. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References Long-Term Follow-up of Ofo: Results from the Open-Label Extension Study (OLE-002)

Frequently Asked Questions (FAQ)

Common questions about Ofo (FAQ)

Q: How is Ofo different from [Similar Drug Name]?

Ofo (Ofloxacin) is classified in official drug information as a second-generation fluoroquinolone antibiotic. While cross-resistance with other fluoroquinolones has been reported, some microorganisms that are resistant to other drugs in this class may remain susceptible to Ofo, according to regulatory documents.

Q: What happens if Ofo is stopped suddenly?

Regulatory information indicates that stopping Ofo before completing the full prescribed course, or frequently skipping doses, may increase the potential for the infection not being fully treated. This may also increase the potential for the development of bacteria that are resistant to antibiotics.

Q: Is Ofo known to cause dependency or withdrawal issues?

Ofo is an antibiotic and is not classified as a controlled or addictive substance by major regulatory authorities. However, official information emphasizes the importance of completing the full course as prescribed to minimize the risk of treatment failure and bacterial resistance.

Q: What if I take too much Ofo by mistake?

Reported symptoms of an overdose in official documents may include dizziness, drowsiness, confusion, nausea, and slurred speech. If an overdose is suspected, official sources indicate emergency medical assistance should be sought immediately.

Q: How quickly is Ofo eliminated from the body?

The elimination of Ofo from the body primarily occurs through the kidneys. Official pharmacokinetic data indicates that the drug's plasma half-life is typically 4 to 5 hours, with the majority of an oral dose being excreted unchanged within 48 hours.

Q: What is the risk of developing a new side effect after using Ofo for a long time?

Official regulatory agencies have advised of the risk of disabling and potentially long-lasting or irreversible side effects associated with fluoroquinolones, involving tendons, muscles, joints, nerves, or mental health. These events have been reported to occur during or up to several months after treatment is finished.

Q: Are there restrictions on consuming alcohol while taking Ofo?

Official drug labels for Ofo generally do not list alcohol as a direct drug-to-drug interaction. However, due to the potential for overlapping side effects like nausea and dizziness, some authoritative reviews suggest the intake of alcoholic beverages should be limited during treatment.

Q: Are there common feelings or sensations associated with taking Ofo?

The official safety profile reports potential adverse reactions affecting the Nervous System, which includes feelings such as dizziness or insomnia, and the Gastrointestinal system, which may include nausea or diarrhea. These are common categories where patient sensations might be reported.

Q: What is the overall success rate mentioned in the clinical trials for Ofo?

Clinical trial summaries describe the measured Clinical Cure Rates and Microbiological Eradication Rates for specific infections in trial populations. These rates are variable and dependent on the particular infection being treated and the patient group studied in the trials.

Q: Are there real-world evidence reports available for Ofo?

Yes, regulatory documents for Ofo incorporate data from post-marketing and observational settings, which are often referred to as real-world evidence. This follow-up data contributes to the overall knowledge base regarding outcomes outside of controlled clinical trials.

Q: Is Ofo available in liquid form?

Yes, Ofo is approved and available in multiple liquid preparations. These include ophthalmic solution (eye drops), otic solution (ear drops), and an intravenous solution for direct administration, in addition to the oral tablet form.

Q: Does Ofo have any known long-term effects on organs like the liver or kidneys?

Patients with pre-existing severe kidney or liver disease require caution because Ofo is metabolized and excreted through these organs. Official documents have linked Ofo to rare instances of acute liver injury and acute renal failure, which are conditions that healthcare providers monitor.

Q: Are there specific symptoms that signal an allergic reaction to Ofo?

Official regulatory warnings for severe skin reactions and hypersensitivity advise watching for symptoms such as hives, skin rash, or large, hive-like swelling, particularly on the face, eyelids, or throat.

Q: Is Ofo a controlled substance?

No, Ofo (Ofloxacin) is an antibiotic in the fluoroquinolone family. Official regulatory authorities do not classify it as a controlled substance.

Q: What if I experience stomach upset after taking Ofo?

Stomach upset is generally classified within the Gastrointestinal disorders category of adverse reactions. Commonly reported symptoms in this category include nausea, diarrhea, and abdominal or stomach pain, as documented in the official safety profile.

Q: Does Ofo cause drowsiness or affect driving ability?

Side effects such as dizziness and drowsiness are listed in the official safety profile under Nervous System Disorders. These are effects that may potentially impact a person's mental alertness.

Q: Why are people talking about Ofo and weight changes?

The official safety profile lists changes in the body's metabolism as potential adverse reactions, including decreased appetite and high blood sugar (hyperglycemia). These physiological changes are factors that could contribute to general discussions regarding weight.

Q: If I miss taking Ofo, what should I do?

If a dose is missed, regulatory information indicates it may be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule continued. Official advice is not to take two doses at the same time.

Q: Is it normal to feel a mild headache after starting Ofo?

Yes, headache is an effect frequently reported in the official safety profile for Ofo and is categorized under Nervous System Disorders.

Q: What information should I provide to my healthcare provider before starting Ofo?

Official warnings state that individuals are advised to report a history of seizures/epilepsy, pre-existing kidney disease, or any prior history of tendon problems related to the use of other fluoroquinolone antibiotics.

Q: Can Ofo affect how well other medications work?

Yes, Ofo has a documented interaction profile because it is metabolized by the CYP3A4 enzyme in the body. This means Ofo can potentially alter the systemic exposure or change the effectiveness of certain other medications taken at the same time.

Q: What happens if Ofo expires?

Regulatory guidance focuses on the safe disposal of medicine that is past its expiration date or is otherwise unused. Official instructions recommend disposing of expired medicine through a drug take-back program or mixing it with an undesirable substance before discarding in household trash.

How should Ofo be stored and disposed of?

How to Store and Dispose of Ofo (Ofloxacin)

The storage and disposal of Ofo (Ofloxacin) must adhere to official regulatory requirements to ensure product stability and safety.

Storage Requirements

Ofloxacin must be stored at room temperature, typically 20 C to 25 C (68 F to 77 F), with storage not above 30 C [Source 2.2, 2.3]. It must be kept away from heat, moisture, and direct light and must not be frozen [Source 2.1]. For safety, the medicine must be stored in a closed container and out of the reach of children [Source 2.1].

Disposal Instructions

Unused or expired Ofloxacin should be disposed of primarily through a drug take-back program [Source 4.1]. If a take-back program is unavailable, the product must be mixed with an undesirable substance, placed in a sealed container, and put in the household trash; it must not be flushed down a sink or toilet [Source 4.2, 4.5].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ofo found in:

A-Z Index: